Lung transplantation for pulmonary hypertension

S. P. Gaine, Jonathan B Orens

Research output: Contribution to journalArticle

Abstract

Although lung transplantation is a viable option for patients with end-stage pulmonary hypertension, it is associated with numerous problems including infection, rejection, and limited long-term survival. Because of these limitations, transplantation should only be considered for patients who are failing maximal medical therapy. Treatment options for patients with pulmonary hypertension that may serve to prolong or obviate the need for transplantation include anticoagulation with warfarin, diuretics, and vasodilators such as calcium channel blockers or continuous intravenous epoprostenol (prostacyclin). The response to medical therapy should be assessed at regular intervals by evaluating exercise tolerance and hemodynamic parameters. Because waiting periods for transplantation now exceed 1.5 to 2 years in the United States, and the response to medications is unpredictable, referral for transplantation should occur when patients become symptomatic. Those who are responding well to medical therapy should be removed from the active transplant waiting list, whereas those who fail therapy should go on to transplant. Utilizing medical therapy and transplantation as complementary treatments will achieve the best potential to improve quality of life and prolong survival.

Original languageEnglish (US)
Pages (from-to)533-540
Number of pages8
JournalSeminars in Respiratory and Critical Care Medicine
Volume22
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Lung Transplantation
Pulmonary Hypertension
Transplantation
Epoprostenol
Therapeutics
Transplants
Exercise Tolerance
Waiting Lists
Survival
Calcium Channel Blockers
Warfarin
Vasodilator Agents
Diuretics
Referral and Consultation
Hemodynamics
Quality of Life
Infection

Keywords

  • Lung transplantation
  • Prostacyclin
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Pulmonary and Respiratory Medicine
  • Critical Care

Cite this

Lung transplantation for pulmonary hypertension. / Gaine, S. P.; Orens, Jonathan B.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 22, No. 5, 2001, p. 533-540.

Research output: Contribution to journalArticle

@article{a0e434ec5d474d1fbd8cf9db0f332142,
title = "Lung transplantation for pulmonary hypertension",
abstract = "Although lung transplantation is a viable option for patients with end-stage pulmonary hypertension, it is associated with numerous problems including infection, rejection, and limited long-term survival. Because of these limitations, transplantation should only be considered for patients who are failing maximal medical therapy. Treatment options for patients with pulmonary hypertension that may serve to prolong or obviate the need for transplantation include anticoagulation with warfarin, diuretics, and vasodilators such as calcium channel blockers or continuous intravenous epoprostenol (prostacyclin). The response to medical therapy should be assessed at regular intervals by evaluating exercise tolerance and hemodynamic parameters. Because waiting periods for transplantation now exceed 1.5 to 2 years in the United States, and the response to medications is unpredictable, referral for transplantation should occur when patients become symptomatic. Those who are responding well to medical therapy should be removed from the active transplant waiting list, whereas those who fail therapy should go on to transplant. Utilizing medical therapy and transplantation as complementary treatments will achieve the best potential to improve quality of life and prolong survival.",
keywords = "Lung transplantation, Prostacyclin, Pulmonary hypertension",
author = "Gaine, {S. P.} and Orens, {Jonathan B}",
year = "2001",
doi = "10.1055/s-2001-18425",
language = "English (US)",
volume = "22",
pages = "533--540",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "5",

}

TY - JOUR

T1 - Lung transplantation for pulmonary hypertension

AU - Gaine, S. P.

AU - Orens, Jonathan B

PY - 2001

Y1 - 2001

N2 - Although lung transplantation is a viable option for patients with end-stage pulmonary hypertension, it is associated with numerous problems including infection, rejection, and limited long-term survival. Because of these limitations, transplantation should only be considered for patients who are failing maximal medical therapy. Treatment options for patients with pulmonary hypertension that may serve to prolong or obviate the need for transplantation include anticoagulation with warfarin, diuretics, and vasodilators such as calcium channel blockers or continuous intravenous epoprostenol (prostacyclin). The response to medical therapy should be assessed at regular intervals by evaluating exercise tolerance and hemodynamic parameters. Because waiting periods for transplantation now exceed 1.5 to 2 years in the United States, and the response to medications is unpredictable, referral for transplantation should occur when patients become symptomatic. Those who are responding well to medical therapy should be removed from the active transplant waiting list, whereas those who fail therapy should go on to transplant. Utilizing medical therapy and transplantation as complementary treatments will achieve the best potential to improve quality of life and prolong survival.

AB - Although lung transplantation is a viable option for patients with end-stage pulmonary hypertension, it is associated with numerous problems including infection, rejection, and limited long-term survival. Because of these limitations, transplantation should only be considered for patients who are failing maximal medical therapy. Treatment options for patients with pulmonary hypertension that may serve to prolong or obviate the need for transplantation include anticoagulation with warfarin, diuretics, and vasodilators such as calcium channel blockers or continuous intravenous epoprostenol (prostacyclin). The response to medical therapy should be assessed at regular intervals by evaluating exercise tolerance and hemodynamic parameters. Because waiting periods for transplantation now exceed 1.5 to 2 years in the United States, and the response to medications is unpredictable, referral for transplantation should occur when patients become symptomatic. Those who are responding well to medical therapy should be removed from the active transplant waiting list, whereas those who fail therapy should go on to transplant. Utilizing medical therapy and transplantation as complementary treatments will achieve the best potential to improve quality of life and prolong survival.

KW - Lung transplantation

KW - Prostacyclin

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=0035184339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035184339&partnerID=8YFLogxK

U2 - 10.1055/s-2001-18425

DO - 10.1055/s-2001-18425

M3 - Article

C2 - 16088699

AN - SCOPUS:0035184339

VL - 22

SP - 533

EP - 540

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 5

ER -